Last month, the DNA-testing company 23andMe secured Food and Drug Administration approval for a new screening for gene-based health risks. Along with celiac disease, Alzheimers, Parkinsons, breast cancer and several other medical conditions, the company can now screen clients for two mutations that have been linked to colorectal cancer.But F.D.A.-approved does not necessarily mean clinically useful. 23andMe relies on much simpler technology than tests that youd get at your doctors office. As a result, the companys tests cannot tell you much about your actual risk of developing the diseases in question.Heres how those tests work and why you should interpret them with caution.

Source: Click here

Facebook Comments